Brainsway stock price target maintained at $19 by H.C. Wainwright
H.C. Wainwright maintained a Buy rating and $19 price target for Brainsway (BWAY), citing expanded insurance coverage for its Deep TMS treatment. The stock trades at $11.93, with a P/E of 52 and PEG of 0.44. Brainsway reported Q2 2026 revenue of $17.1M, exceeding estimates, and raised its full-year outlook. The company also partnered with Inland Psychiatric Medical Group.
How this was made
The 30-second read
Why it matters
Analyst price‑target raise and coverage expansion suggest near‑term upside, but market impact may be muted by the company's small size.
Market read
Positive analyst coverage could lift BWAY modestly; sector may see incremental interest.
What to watch
Potential reimbursement challenges and competition from other TMS providers could temper growth.
Background
Brainsway (NASDAQ:BWAY) develops Deep Transcranial Magnetic Stimulation devices for OCD and depression. The firm recently reported Q2 2026 results and expanded insurance coverage.
Ticker impact
H.C. Wainwright reiterated a Buy rating and raised the price target to $19 after reporting Q2 revenue beat and expanded insurance coverage for Brainsway's Deep TMS treatment.
likely upward pressure as investors price in higher target and coverage expansion
The new target and coverage news are fresh and material, but the company is a micro‑cap with limited liquidity.
Market effects
Expanding insurance coverage may boost the broader neuro‑stimulation and mental‑health device sector.
U.S. mental‑health device market sees incremental demand.
Limited to U.S. biotech and mental‑health treatment space.
Counterpoint
The high P/E and modest revenue base could limit upside; investors may wait for larger scale data.
Key entities
- companyBrainsway
Developer of Deep TMS treatment devices.
- analyst_firmH.C. Wainwright
Equity research firm that issued the upgraded rating.
